Pharmacovigilance Operations – Clinical trials

Case processing (SAEs)

The data generated from clinical trials tends to be more complete than that received through typical channels of spontaneous reporting. Likewise, the steps for follow-up are often far easier to take. Nonetheless, you will need to demonstrate consistently that your reporting process is adequately specified and resourced to the task.

Clinical trial safety

Maintaining safety within clinical trials is of paramount importance to any pharmaceutical company wishing to bring new products to the marketplace or diversify their existing products.

SUSAR – Suspected Unexpected Serious Adverse Events Reporting

Electronic Reporting of Suspected Unexpected Serious Adverse Events (SUSARS) is now mandatory in many global territories.

Periodic reporting (DSURs)

Additionally to the need for expedited reporting of SUSARs, Development Safety Update Reports (DSURs) should be submitted to regulatory authorities and Ethics Committees throughout the clinical trial or on request. The DSUR takes into account all new available safety information received during the reporting period.

This site uses cookies to personalise and customise your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Cookie Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

  • __cfduid

Decline all Services
Accept all Services